<DOC>
	<DOCNO>NCT00993473</DOCNO>
	<brief_summary>The primary study objective compare rate `` hypoglycemia '' ( composite outcome follow hypoglycemia event : symptomatic hypoglycemia episode , low continuous glucose monitoring system ( CGMS ) excursion confirm fingerstick blood glucose ( FSBG ) , low FSBG reading perform time ) child treat Lantus ( insulin glargine ) Neutral Protamine Hagedorn ( NPH ) insulin . Secondary objective compare insulin glargine NPH term : - rate specific type hypoglycemia : symptomatic , severe , nocturnal , nocturnal symptomatic , severe nocturnal symptomatic hypoglycemia - HbA1c change baseline end-of-treatment , HbA1c end-of-treatment - percentage patient reach HbA1c le 7.5 % ( target value ) end treatment - average blood glucose whole trial end trial , estimate continuous glucose monitoring ( CGM ) , blood glucose variability</brief_summary>
	<brief_title>6-month Comparison Morning Lantus Versus Neutral Protamine Hagedorn Insulin Young Children With Type 1 Diabetes</brief_title>
	<detailed_description>Screening phase : 2 4 week Treatment phase : 24 week At randomization , patient stratify respect baseline HbA1c level ( &lt; 8.5 % ≥8.5 % ) hypoglycemic event rate ( number CGMS hypoglycemic excursion &lt; 0.5 ≥0.5 event per 24 hour ) . Following randomization , trial basal insulin initiate up-titrated within first 12 week reach stable dose . Follow-up phase : 2 week All Phases : 28 30 week</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Protamines</mesh_term>
	<criteria>Inclusion criterion : Pediatric patient type 1 diabetes mellitus age least one year le 6 year screen , sign write informed consent obtain parent legal guardian participate study Exclusion criterion : Diagnosis type 1 diabetes less one year HbA1c screening &gt; 12 % &lt; 6 % Diabetes type 1 diabetes Parents patient willing undergo study assessment treatment , include home blood glucose monitoring , Continuous Glucose Monitoring System ( CGMS ) sensor placement maintenance site home , multiple daily insulin injection , visit , dictate protocol ( telephone available patient may undergo visit person ) Patients family 6 day total ( necessarily continuous ) useable CGMS data obtain ( either home sensor replacement , sensor replacement site additional screening visit need ) screen CGMS evaluation Visit 2 randomization visit Patients treat insulin pump therapy two month prior screen History primary seizure disorder History severe hypoglycemic episode accompany seizure and/or coma , diabetic ketoacidosis lead hospitalization care emergency ward , 2 month prior screen visit Need chronic treatment acetaminophen ( paracetamol ) contain medication Serum creatinine &gt; 2.0mg/dL screen Serum ALT AST great 3x upper limit normal patient 's age gender , screen Hemoglobin &lt; 10g/dL , platelet count le 100,000/cu mm , screen Treatment pharmacologic antihyperglycemic oral agent 3 month time Treatment noninsulin antihyperglycemic medication ( eg , Symlin® ) 3 month prior screen Treatment systemic glucocorticoid within month prior screen Above information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>